Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic e...

Full description

Bibliographic Details
Main Authors: Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi
Format: Article
Language:English
Published: Nature Publishing Group 2017-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-00728-9

Internet

https://doi.org/10.1038/s41467-017-00728-9

Similar Items